NEW YORK, April 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceutical Key Trends 2011 – Biosimilar Market Overview

http://www.reportlinker.com/p0487117/Pharmaceutical-Key-Trends-2011-–-Biosimilar-Market-Overview.html

Introduction

In 2009, the combined biosimilars market size for the US and five major European markets was $150m. With more than 30 branded biologics with sales of $51bn set to lose patent exclusivity between 2011 and 2015, Datamonitor forecasts that the global biosimilar market will grow from $243m in 2010 to $3.7bn in 2015.

Features and benefits

* Overview of the biosimilar market, with biosimilar definitions in the US, EU and Japan, plus historical and forecast biosimilar sales out to 2015.

* Insight into the key drivers and resistors to biosimilar uptake in the developed and emerging markets.

* Assesses key factors determining successful biosimilar market access, and examines the major biosimilar players and the strategies they implement.

* Analyses biosimilar uptake in the five main European markets and provides insight into the future opportunities for biosimilar players.

Highlights

Due to their complexity, cost, and development risks, biosimilar production and commercialization in developed markets is concentrated among only a handful of pharma companies, all of which are established generics players.

Despite the Introduction of approval pathways in the US, EU, and Japan, the growing use of biologics, and the need for more cost-effective treatments, all of which help drive biosimilar uptake, there remain a large number of barriers to uptake.

There are relatively few factors which limit the growth of the biosimilar industry in the developing markets, although the Introduction of biosimilar pathways will restrict market access to many domestic biosimilar players, while low purchasing power and a high proportion of out-of-pocket expenditure, coupled with brand loyalty, limit access.

Your key questions answered

* Evaluate the evolving regulatory environment in the US, EU and Japan, and how this impacts biosimilar market access and uptake.

* Gain insight into the deal types among branded, generic and biosimilars players to either enter or bolster their position in the biosimilars market.

* Identify which branded biologics are facing patent expiry and provide significant opportunities for biosimilar developers.

Executive Summary

Introduction

Strategic scoping and focus

Key findings

Related reports

Upcoming related reports

2. GLOBAL BIOSIMILAR MARKET SIZE

[Missing title]

Biosimilar definitions

Biosimilar sales in 2009

Biologic sales exposed to potential biosimilar competition during 2011–15

Forecast biosimilar sales, 2010–15

Profitability of biosimilars versus branded biologics and generics

3. DRIVERS AND RESISTORS TO BIOSIMILAR UPTAKE

Drivers and resistors to biosimilar uptake in the developed markets

Drivers of biosimilar uptake in developed markets

Neutral factors impacting biosimilar uptake in developed markets

Resistors to biosimilar uptake in developed markets

Drivers and resistors to biosimilar uptake in Brazil, Russia, India, and China

Drivers of biosimilar uptake in emerging markets

Resistors impacting biosimilar uptake in emerging markets

4. BIOSIMILAR MARKET ACCESS

Key factors in determining the success of biosimilar market access

Biosimilar development timeline

Biosimilar development costs

Pros and cons of developing and manufacturing biosimilars in developing markets

Biosimilar approval pathways

Biosimilar producers face a challenging patent environment

Biosimilar pricing in developed markets

Partnerships help drive growth of the biosimilars industry

5. KEY BIOSIMILAR PLAYERS

Key biosimilar players in the developed and emerging markets

Key biosimilar players in the developed markets

Key players in the emerging markets

6. BIOSIMILARS BY GEOGRAPHIC MARKET

Biosimilar launches

US biosimilars market

Biosimilars in the five major EU markets

Japanese biosimilars market

Australian biosimilars market

BRIC biosimilars market

7. BIOSIMILAR UPTAKE

Uptake of biosimilar somatropin, filgrastim and epoetin

Biosimilar somatropin

Biosimilar filgrastim

Biosimilar epoetin

8. OPPORTUNITIES FOR THE BIOSIMILAR INDUSTRY

Branded biologic patent expiries present opportunities for the biosimilar industry

Biologic patent expiries in the US

Biologic patent expiries in the five major EU markets

Biologic patent expiries in Japan

Biosimilars in development internationally

Biosimilar MAbs and second-generation biosimilars offer the greatest commercial potential

9. BIBLIOGRAPHY

Publications and online articles

APPENDIX

Exchange rates used in this report

To order this report:

: Pharmaceutical Key Trends 2011 – Biosimilar Market Overview

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker